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ABSTRACT
Background: Allergen specific immunotherapy is highly effective, but adverse events may occur during treat-
ment. Peptide-based immunotherapy has been proposed as one of new strategies for reduction of allergic ad-
verse reactions. We examined the possibility of candidate peptides for the development of peptide-based im-
munotherapy for Japanese cedar pollinosis.
Methods: Twelve Cry j 1-specific T-cell lines were established from peripheral blood mononuclear cells
(PBMC) of 12 patients with Japanese cedar pollinosis. Using these T-cell lines, 37 Cry j 1-derived overlapping
peptides were assessed for their proliferative responses and cytokine production.
Results: Four peptides corresponding to the Cry j 1 sequence were able to induce proliferative responses to
more than one T-cell line: p61―80 (312; 25.0%); p115―132 (212; 16.6%); p206―225 (412; 33.3%); and
p337―353 (512; 41.7%). Furthermore, T-cell lines generated from 11 of 12 donors (91.7%) responded to at
least one of these four peptides. On the other hand, the pattern of cytokine production from Cry j 1-specific T-
cell lines varied. Moreover, cytokine production patterns by stimulation with Cry j 1 peptide did not reflect those
by stimulation with Cry j 1 protein.
Conclusions: Our results suggest four Cry j 1-derived peptides (p61―80, p115―132, p206―225 and p337―
353) may be considered to be the immunodominant T-cell epitopes of the Cry j 1 molecule, and can be useful
for the design of peptide-based immunotherapy for the management of Japanese cedar pollinosis.
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INTRODUCTION
Allergic rhinitis is characterized by allergen-specific
IgE production and activation of effector cells includ-
ing eosinophils, mast cells, and basophils. These
events are under regulation by a distinct subset of T
lymphocytes, T helper 2 (Th2) cells that preferen-
tially produce interleukin (IL)-4, IL-5, and IL-13.
Thus, allergic diseases have been recognized as an
inadequate peripheral regulation of allergen-specific
T-cells in individuals.
Allergen immunotherapy to allergic individuals in-
duces a state of clinical and immunological tolerance;
therefore, allergen immunotherapy is recognized as a
highly effective treatment for allergic rhinitis. Evi-
dence has accumulated indicating that immunother-
apy inhibits allergen-driven Th2 responses by im-
mune deviation in favor of Th1 responses andor by
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Table 1 Clinical characteristics of the polen alergic donors
Therapeutic historybOther alergensaSymptomatic period (m)RAST scoreAge/Sex Patients
MEM, R60427MAR-1
None―24236MAR-2
ME―12250FAR-3
MEM60338MAR-4
MEM36337MAR-5
ME―72437MAR-6
MEM, R60225MAR-7
MEM48334MAR-8
ME―72433MAR-9
MEM36332MAR-10
MER72348FAR-11
MER24216MAR-12
a M; house dust mites, R; ragweed.
b ME; medications using oral antihistamines.
inducing T regulatory responses which produce the
inhibitory cytokines such as IL-10 and transforming
growth factor (TGF)-β.1-3 Recently, intended as a
novel strategy for allergen immunotherapy, the use of
peptides which retain immunogenicity but are of in-
sufficient length to cross-link IgE on the surface of
mast cells, thereby reducing the risk of inducing ana-
phylaxis, has been introduced.4,5 Actually, Oldfield et
al. have demonstrated that overlapping Fel d 1-
derived T-cell peptides produced hyporesponsiveness
to rechallenge with peptides as well as whole aller-
gen, both clinically and in terms of in vitro T cell reac-
tivity.6,7 Moreover, treatment using these peptides
showed significant improvements in clinical outcome
measurements such as the allergen-induced nasal
and bronchial reactions, and asthmarhinitis quality
of life.8
Japanese cedar pollinosis caused by exposure to
Cryptomeria japonica pollen is one of the most preva-
lent allergic diseases in Japan, and two major aller-
gens, Cry j 1 and Cry j 2, have been isolated and spe-
cific IgE have been detected in patients suffering
from pollinosis.9,10 To date, a number of HLA class II-
restricted Cry j 1 and Cry j 2 epitopes defined by
CD4+ T cell have been identified.11-14 Among these
epitopes, Hirahara et al. have reported the develop-
ment of a hybrid peptide in which 3 dominant T-cell
determinants in Cry j 1 and 4 in Cry j 2 have been
considered to be potential therapeutic agents for
Japanese cedar pollinosis.15 They chose p212―224,
p235―247 and p312―330 from among T cell epitopes
identified in the Cry j 1 sequence. Similarly, Sone et
al. have also reported an artificial polypeptide which
contains two (p108―120 and p211―225) and three T
cell epitopes chosen from Cry j 1 and Cry j 2 se-
quences, respectively.12 As expected, this polypeptide
was able to stimulate more efficiently PBMC obtained
from allergic patients as compared with individual
peptides. To explore the possibility of other candidate
peptides for the development of peptide-based immu-
notherapy for Japanese cedar pollinosis, we investi-
gated helper T cell responses to overlapping peptides
derived from Cry j 1 sequence using Cry j 1-specific T
cell lines obtained from patients with Japanese cedar
pollinosis.
METHODS
SUBJECTS
Peripheral blood mononuclear cells were obtained
from twelve patients whose diagnosis was based on
clinical symptoms, positive skin prick tests, and ra-
dioallergosorbent test (RAST) scores against Japa-
nese cedar pollen. The study was approved by the In-
stitutional Review Board at the University of
Yamanashi, University Hospital. Written informed
consent was obtained from each individual. Details of
the clinical data are shown in Table 1.
PURIFICATION OF Cry j 1 AND PEPTIDE SYN-
THESIS
Cry j 1, a major allergen of Cryptomeria japonica
(Japanese cedar) pollen, was purified as described.9,16
Briefly, dry pollen was defatted with ether, placed in
0.125 M ammonium bicarbonate, and stirred for 2
days at 4℃. Solid ammonium sulphate was added to
the extract to 100% saturation. The precipitate was
dissolved in 0.01 M Tris-HCL, pH 7.8, and dialyzed
against the same buffer. A sample of this preparation
was applied to a DEAE-cellulose column (Whatman,
Madison, U.K.) and eluted with the same buffer. The
eluate was dialyzed against 0.01 M acetate buffer (pH
5.0) and applied to a CM-cellulose column (What-
man). The column was eluted first with 0.01 M ace-
tate buffer, and then with 0.1 M phosphate buffer, pH
7.0. The second elute was concentrated and purified
by molecular sieving HPLC (Bio Sil TSK-250; BioRad,
Hercules, CA). A fraction thus obtained contained 41
and 46 kDa proteins as determined by SDS-PAGE
Peptide Candidates for Cry j 1-Specific Immunotherapy
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Table 2 HLA class I genotypes of the polen alergic donors
DPDQDR Patients
DPB1＊0202DQB1＊0301DQA1＊0501DRB3＊0301DRB1＊1403AR-1
DPB1＊0402DQB1＊0602DQA1＊0102DRB5＊0101DRB1＊1501
DPB1＊0501DQB1＊0401DQA1＊0301DRB4＊0101DRB1＊0405AR-2
DPB1＊0301DQB1＊0402DQA1＊0301DRB4＊0101DRB1＊0410
DPB1＊0501DQB1＊0501DQA1＊0101DRB1＊0101AR-3
DPB1＊0901DQB1＊0601DQA1＊0103DRB5＊0102DRB1＊1502
DPB1＊0501DQB1＊0401DQA1＊0301DRB4＊0101DRB1＊0405AR-4
DQB1＊0303DQA1＊0301DRB4＊0101DRB1＊0901
DPB1＊0501DQB1＊0303DQA1＊0301DRB4＊0101DRB1＊0901AR-5
DPB1＊0901DQB1＊0601DQA1＊0103DRB5＊0102DRB1＊1502
DPB1＊0501DQB1＊0401DQA1＊0301DRB4＊0101DRB1＊0405AR-6
DQB1＊0502DQA1＊0101DRB3＊0202DRB1＊1401
DPB1＊0201DQB1＊0301DQA1＊0501DRB3＊0101DRB1＊1403AR-7
DPB1＊0901DQB1＊0604DQA1＊0102DRB3＊0301DRB1＊1302
DPB1＊0202DQB1＊0503DQA1＊0101DRB3＊0202DRB1＊1405AR-8
DPB1＊0201DQB1＊0601DQA1＊0103DRB1＊0803
DPB1＊0201DQB1＊0401DQA1＊0301DRB4＊0101DRB1＊0405AR-9
DPB1＊0501DQB1＊0604DQA1＊0102DRB3＊0301DRB1＊1302
NDNDNDAR-10
DPB1＊0402DQB1＊0601DQA1＊0103DRB5＊0102DRB1＊1502AR-11
DPB1＊0501DQB1＊0604DQA1＊0102DRB3＊0301DRB1＊1302
DPB1＊0201DQB1＊0601DQA1＊0103DRB5＊0102DRB1＊1502AR-12
DPB1＊0901DQB1＊0301DQA1＊0501DRB3＊0202DRB1＊1402
ND; not determined.
analysis (data not shown).
Peptides were synthesized from the amino acid se-
quence of Cry j 1 reported by Griffith et al.17 and
Sone et al.,18 by utilizing a solid-phase simultaneous
multiple peptide synthesizer PSSM-8 (Shimadzu,
Kyoto, Japan) based on Fmoc strategy with PyBOP-
HOBt-NMM (1 : 1 : 1.5). Peptides overlapping by 6 to
15 amino acids and covering the entire Cry j 1 mole-
cule were produced.13 All peptides were purified by
C18 reverse-phase high-performance liquid chroma-
tography (Millipore Corp., Bedford, MA).
HLA CLASS II TYPING
Genotypes of HLA class II (DR, DQ, DP) alleles of
the pollen allergic donors were determined by hy-
bridization of HLA-DR, DQ, and DP genes amplified
by polymerase chain reaction with sequence-specific
oligonucleotide probes, as described previously.13
ESTABLISHMENT OF Cry j 1-SPECIFIC T-CELL
LINES
T-cell lines were generated by stimulating 1 × 105
PBMC with Cry j 1 (2.5 μgml) in RPMI-1640 me-
dium (GIBCO, Grand Island, N.Y.) supplemented
with 2 mM L-glutamine, 100 unitsml penicillin, 100
μgml streptomycin, and 10% pooled, heat-inactivated
normal human serum in each of sixty wells of 96-well
flat-bottomed culture plates (Nunc, Roskilde, Den-
mark). After 7 days, irradiated (30 Gy) autologous
PBMC at 1 × 105well, human rIL-2 (10 Uml), hu-
man rIL-4 (10 Uml), and Cry j 1 (2.5 μgml) were
added to culture wells with T-cell blasts and main-
tained for an additional 7 days. Antigen-induced pro-
liferation of the T-cell blasts was assayed, and the cul-
ture wells exhibiting Cry j 1-specific proliferation
were transferred and propagated in a 24-well plate.
PROLIFERATION ASSAYS
T cells were co-cultured with irradiated (30 Gy) au-
tologous PBMC (1 × 105well) in the presence of Cry
j 1 (1.25 μgml) in 96-well flat-bottomed plates for 72
hours and pulsed with 1 μCiwell of [3H] TdR for the
last 24 hours, and the incorporated radioactivity was
measured by liquid scintillation counting. Stimulation
indices (S.I.) were calculated by comparing the
antigen-containing wells with those containing me-
dium alone. In the case where synthesized peptides
were used as antigen, PBMC (1.5 × 105well) were
cultured with various overlapping peptides (2.5 μM)
in culture medium for 2 hours at 37℃, after which ex-
cess peptides and nonadherent cells were removed
by gently washing the plates three times with RPMI-
1640 media containing 3% human serum. The remain-
ing adherent cells were irradiated at 30 Gy and used
as antigen presenting cells (APC).
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Fig. 1 Proliferative response and cytokine production by a Cry j 1-specific T cel line es-
tablished from patient AR-1. Cry j 1-specific T-cel line established from patient AR-1 re-
sponded 5 diferent peptides; p108―125, p201―220, p206―225; p230―250, and p337―353.
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QUANTIFICATION OF IL-4 AND IFN-γ IN SUPER-
NATANT OF THE T CELL LINES
Culture supernatants of the same T cell lines evalu-
ated for proliferative responses, after stimulation by
APC plus antigen, were collected immediately before
the addition of [3H] TdR and stored in aliquots at
－80℃ until the lymphokine concentrations were de-
termined. IL-4 ELISA and IFN-γ ELISA (MEDGENIX,
Fleurus, Belgium) were used to quantify IL-4 and
IFN-γ in the supernatants according to the manufac-
turer’s instructions.
RESULTS
ESTABLISHMENT OF Cry j 1-SPECIFIC T-CELL
LINES
We generated Cry j 1-specific T-cell lines from PBMC
obtained from all 12 pollen allergic donors (Table 1,
2). After 3 x in vitro stimulation, the outgrowing T
cells were tested for their proliferative responses in
the presence of Cry j 1 protein and irradiated autolo-
gous PBMC. Moreover, these Cry j 1-specific T cell
lines were tested for their production of IFN-γ and IL-
4. As expected, these T-cell lines produced various
amounts of IFN-γ andor IL-4 in response to Cry j 1
presented by autologous PBMC. Figure 1 shows the
Peptide Candidates for Cry j 1-Specific Immunotherapy
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Table 3 Proliferative responses to Cry j 1-derived peptides of Cry j 1-specific T-cel lines obtained from the polen alergic 
donorsa.
Total
Responses
Patients
Peptide
AR-12AR-11AR-10AR-9AR-8AR-7AR-6AR-5AR-4AR-3AR-2AR-1
1/12＋＋p13―32
3/12＋＋＋＋＋p61―80
1/12＋p71―90
1/12＋p81―100
1/12＋p86―105
1/12＋＋＋p108―125
2/12＋＋＋＋p115―132
1/12＋＋p127―143
1/12＋＋＋p201―220
4/12＋＋＋＋＋＋p206―223
1/12＋＋＋p230―250
1/12＋p261―280
1/12＋＋＋p271―290
1/12＋＋p301―321
5/12＋＋＋＋＋＋＋＋＋＋＋p337―353
a＋; 5≦S.I.＜50,＋＋; 50≦S.I.＜100, ＋＋＋; 100≦S.I.
representative data obtained from patient AR-1.
PROLIFERATIVE RESPONSES TO Cry j 1-
DERIVED OVERLAPPING PEPTIDES
Next, proliferative responses of each established T-
cell lines against autologous PBMC pulsed with Cry j
1-derived overlapping peptides were investigated. As
shown in Figure 1, Cry j 1-specific T-cell line estab-
lished from patient AR-1 responded 5 different pep-
tides; p108―125, p201―220, p206―225, p230―250, and
p337―353. Similarly, all established Cry j 1-specific T-
cell lines were tested for proliferative responses to
Cry j 1-derived overlapping peptides. Table 3 summa-
rizes the proliferative responses to Cry j 1-derived
overlapping peptides. Among a panel of 37 overlap-
ping peptides corresponding to the amino acid se-
quence of Cry j 1, 15 peptides were able to stimulate
at least one T-cell line tested. These peptides repre-
sent a widely dispersed set of epitopes from the N- to
the C-terminus of the Cry j 1 molecule. It is highly
likely that these antigenic peptides include the T-cell
epitopes of Cry j 1. Notably, 4 peptides were able to
induce proliferative responses to more than two T-cell
lines: p61―80 (312; 25.0%); p115―132 (212; 16.6%);
p206―225 (412; 33.3%); and p337―353 (512; 41.7%).
Furthermore, T-cell lines generated from eleven of
twelve donors (all except AR-8) responded to at least
one of these four peptides. Accordingly, these results
suggest that these 4 peptides may be immunodomi-
nant T-cell epitopes of Cry j 1.
CYTOKINE PRODUCTION BY STIMULATION
WITH Cry j 1 AND Cry j 1-DERIVED OVERLAP-
PING PEPTIDES
Nine of the 12 established T-cell lines were assessed
for cytokine production by stimulation with Cry j 1
protein. However, the pattern of cytokine production
from Cry j 1-specific T-cell lines varied. Two T-cell
lines obtained from AR-1 and AR-2, produced IL-4 pre-
dominantly (Th2 pattern), whereas 4 (AR-6, -7, -8, and
-9) produced IFN-γ predominantly (Th1 pattern), and
3 (AR-3, -4, and -5) produced IFN-γ and IL-4 equally
(Th0 pattern), as shown in Table 4. Patients’ RAST
scores, the length of their clinical experience, and
their therapeutic history did not appear to bear any
relationship to their pattern of cytokine production
(data not shown).
Next, the cytokine production by stimulation with
37 overlapping peptides was also assessed. Similar to
proliferation responses, each T-cell line except AR-5,
produced cytokines by stimulation with identical pep-
tides that showed proliferative responses (data not
shown). However, cytokine production patterns by
stimulation with Cry j 1 peptide did not reflect those
by stimulation with Cry j 1 protein (Table 4). Al-
though most T-cell lines reactive with Cry j 1-derived
peptides produced some IL-4 irrespective of the
amount of IFN-γ production. Interestingly, however,
the T-cell lines obtained from patients AR-3 and AR-8
secreted IFN-γ but failed to produce IL-4 in recogni-
tion of the peptides, p86―105 and p271―290, respec-
tively. For further characterization of these two pep-
tide specific T-cell lines, these T-cell lines were incu-
bated with peptide-pulsed APC during various peri-
Masuyama K et al.
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Table 4 Cytokine production profiles of Cry j 1-specific T-cel lines obtained from the polen alergic donors
Patients
Antigens
AR-9AR-8AR-7AR-6AR-5AR-4AR-3AR-2AR-1
(pg/ml)49/15204/4659/20665/131393/316550/50939/34437/1410174/877aCry j 1 protein
82/127p13―32
269/46p61―80
37/＜10p71―90
39/32p81―100
73/＜10p86―105
116/638p108―125
480/218＜8/109p115―132
23/118p127―143
36/87p201―220
27/1295/＜1018/2751/80p206―223
51/58p230―250
57/35p261―280
91/＜10p271―290
127/115p301―321
203/93131/98127/21444/36p337―353
a The values indicate IFN-γ/IL-4 production, respectively.
ods (24, 48, and 72 hours), and at which times culture
supernatants were collected for the determination of
cytokine concentrations. These two T-cell lines failed
to produce IL-4, while producing large amounts of
IFN-γ and undergoing considerable proliferation
throughout these three incubation periods (data not
shown). Moreover, cultures using various peptide
concentrations (2.5, 5, and 10 μM) were also per-
formed, however; the same patterns of cytokine pro-
duction were observed (data not shown). These re-
sults suggest that p86―105 and p271―290 are likely to
be Cry j 1-derived Th1 epitopes.
DISCUSSION
Allergen-specific immunotherapy is a highly effective
treatment in patients with IgE-dependent diseases in-
cluding insect venom anaphylaxis and allergic rhini-
tis. However, the administration of natural allergen
extracts might occasionally give rise to adverse
events due to severe IgE mediated reactions, there-
fore; several new strategies have been developed to
reduce the potential to cross-link IgE on mast cells
while still containing the relevant T-cell epitopes. As a
new approach, synthetic peptides corresponding to T-
cell epitopes of the allergen have been evaluated in
various studies for peptide-based immunotherapy.
More recently, a clinical immunotherapy trial that
used synthetic peptides of allergens was also re-
ported.8,19,20 One of the advantages of peptide-based
immunotherapy may be related to the insufficient
length to cross-link IgE on the surface of mast cells,
thereby eliminating the risk of induction of anaphy-
laxis. Another advantage is that immunotherapy can
be accomplished within a shorter period of time us-
ing a relatively high-dose injection of antigenic pep-
tides. Fellrath et al. have designed a double-blind,
placebo-controlled phase I clinical trial in patients hy-
persensitive to bee venom using 3 long synthetic
overlapping peptides mapping the whole sequence of
phospholipase A2, a major bee venom allergen, and
demonstrated that there was peptide-specific T-cell
hyporesponsiveness and an increase of IL-10 and
IFN-γ secretion by stimulation with peptides in the
peptide group.20 On the other hand, Kay A.B. and col-
leagues have demonstrated that 12 synthetic overlap-
ping peptides encompassing most of the T-cell epi-
topes of the major cat allergen Fel d 1 can induce T
cell tolerance in animal experiments and these pep-
tides have been shown to decrease the amount of pro-
liferation as well as cytokine production in cat allergic
patients.6,7 Moreover, this treatment has also been re-
ported to have potential for inhibiting upper and
lower airway outcome measurements in a pilot
study.8 Thus, peptide-based immunotherapies have
been shown to be effective for bee venom and cat al-
lergen.
In the present study, we demonstrated that four
peptides of Cry j 1 (p61―80, p115―132, p206―225 and
p337―353) activated more than one T-cell line. Fur-
thermore, T-cell lines generated from eleven out of
twelve donors reacted with at least one of these four
peptides. Therefore, a mixture of these four peptides
may be a useful cocktail for peptide-based immuno-
therapy for patients sensitive to Cry j 1. To date, Hira-
hara et al. and Sone et al. have reported on the bene-
fit of the hybrid or polypeptides consisting of Cry j 1-
derived T cell epitopes for the development of
peptide-base immunotherapy.12,15 These hybrid pep-
Peptide Candidates for Cry j 1-Specific Immunotherapy
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tides or polypeptides would have superior potential
for inducing T-cell proliferative responses as com-
pared with a mixture of the T-cell determinants. How-
ever, the clinical efficacy in immunotherapy using
these peptides has yet to be reported. Hirahara et al.
and Sone et al. have selected a total 4 different pep-
tides, p108―120, p211―225, p235―247, and p312―330
from T cell-epitopes identified in the Cry j 1 se-
quence. In our study, p206―225 inducing T-cell prolif-
erative responses in 412 (33.3%) was the identical
peptide which they selected. Alternatively, 2 other
peptides, p61―80 and p337―353 have also been shown
to induce proliferative responses in relative high fre-
quency, 312 (25.0%) and 412 (41.7%), respectively.
Hori et al. have demonstrated a significant positive as-
sociation between Japanese cedar pollinosis and
HLA-DPB1*0501 (79.2% in patients versus 60.6% in
controls).14 Furthermore, they found that p214―222
was the minimal antigenic site of the immunodomi-
nant peptide for the HLA-DPB1*0501 restricted T
cells. Similar to p206―225, the p61―80 peptide has
also been reported to be presented in the context of
HLA-DPB1*0501 alleles as T-cell defined epitope.11
HLA-DPB1*0501 is one of the most frequently ex-
pressed HLA-DP common alleles in the Japanese
population, therefore; these two peptides may be use-
ful for peptide-based immunotherapy. It is notewor-
thy that T cell lines generated from some DPB1*0501
negative donors were able to proliferate in response
to p61―80 or p206―225 peptides, suggesting that
these two peptides may be recognized in the context
of any other HLA class II. With respect to another
peptide, p337―353, the restriction element remains
unknown. Ikagawa et al. showed that Cry j 1 p335―
346 was presented in the context of HLA-DRA +
DRB3*0301, however; the frequency of HLA-
DRB3*0301 is less than 20% in the Japanese popula-
tion.13 Therefore, the p337―353 peptide may also be
an immunodominant T cell epitope that is presented
by multiple HLA class II molecules. Another possibil-
ity is that the p337―353 peptide may be more immu-
nogenic among Cry j 1-derived T cell epitopes. Thus,
for development of a broadly applicable peptide-based
immunotherapy, universal T cell epitopes that are im-
munogenic in individuals of many HLA haplotypes
should be identified, selected, and used.
In general, it is accepted that PBMC of allergic pa-
tients preferentially induce Th2 rather than Th1 re-
sponses under stimulation with certain allergens;
however, proteins or longer peptides containing mul-
tiple epitopes may induce various T-helper responses,
and the extent of T-helper responses to each epitope
may also vary. Actually, Sone et al. indicated that the
p191―205 peptide presented by HLA-DRB1*0901 and
HLA-DQB1*0602 molecules could preferentially in-
duce Th2 and Th0, respectively.11 Gardner et al. dem-
onstrated that high dose allergen stimulation of T
cells induced expansion of IFN-γ + T cells, apoptosis
of CD4+IL-4+ T cells and T cell anergy in house dust
mite allergic patients.21 Thus, other factors such as
HLA class II allele, the allergic status of the donor,
type of antigens and their concentration, might also
influence immune responses in individuals. Interest-
ingly, Cry j 1-specific T-cell lines obtained from AR-3
and AR-8 showed Th1 responses to p86―105 and
p271―290, respectively. These T-cell lines secreted
IFN-γ, but not IL-4 regardless of the time course and
antigen concentrations. Th1 cells have inhibitory ef-
fects on Th2 function and have been shown to pre-
vent airway inflammation in mouse models.22 Alterna-
tively, Szabo et al. have demonstrated that Th1-
associated transcription factor, T-bet not only induced
Th1 development but also actively suppressed Th2
differentiation in vitro.23 Thus, allergen-specific Th1
cells appear to have a suppressive function to Th2 re-
sponses to allergen, however; it remains unclear how
allergen-specific Th1 cells are interrelated to other
regulatory T cell subsets including naturally occur-
ring CD4+CD25+ T cells, Tr1, and Th3 cells, in aller-
gic disease. Furthermore, there is little information
regarding the relation between the nature of the pep-
tide and the clinical efficacy in peptide-based immu-
notherapy. A better understanding of the nature of
peptides and the specificity of Cry j 1-specific T cell
responses in allergic patients is necessary to better
design, and develop more effective peptide-based im-
munotherapy in the future.
Taken together, our data indicated that four Cry j 1-
derived peptides (p61―80, p115―132, p206―225 and
p337―353) may be considered to be the immuno-
dominant T-cell epitopes of the Cry j 1 molecule, and
can be useful for the design of broadly applicable effi-
cacious peptide-based immunotherapy for the man-
agement of Japanese cedar pollinosis.
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